Novartis drops elinogrel outright
This article was originally published in Scrip
Novartis has dealt another blow to its late-stage antiplatelet candidate elinogrel under cover of a major restructuring announcement. While announcing swingeing cuts to its US primary care sales force (scripintelligence.com, 13 January 2012), Novartis has also dropped elinogrel, once tipped as a blockbuster but quietly refocused in the pipeline last year.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.